

1st UK INTERDISCIPLINARY BREAST CANCER SYMPOSIUM

Monday 15th - Tuesday 16th January 2018
Manchester Central Convention Centre

PROVISIONAL PROGRAMME, ABSTRACT SUBMISSION & REGISTRATION INFORMATION

ABSTRACT SUBMISSION NOW OPEN
Deadline 5pm, Monday 25th September

REGISTRATION NOW OPEN

We look forward to welcoming you to the 1st UK Interdisciplinary Breast Cancer Symposium on 15th-16th January 2018, to be held at Manchester Central Convention Centre.

This meeting has the unambiguous aim of being the UK's premier breast cancer conference. Treatment of breast cancer has for many years been dependent on the interaction of professionals from many disciplines. Research into improving our understanding of this complex disease and prospects for improving its prevention and treatment also require interdisciplinary collaboration to make meaningful advances.

We have therefore brought together UK bodies representing the major disciplines in its treatment and research to create this exciting new venture.

We are delighted to be able to offer an outstanding faculty that should be of interest to all professionals and patient advocates with an active interest in breast cancer.

KEYNOTE LECTURES:

Breast Cancer Research: Past and Future
Dr Marc Lippman, USA

Innovation in Neoadjuvant Chemotherapy
Dr Laura Esserman, USA

Understanding Risk
Professor Sir David Spiegelhalter, UK

Breast Cancer Prevention for the Population at Large
Professor Jack Cuzick, UK

Completion of The Cancer Genome Atlas
Dr Chuck Perou, USA

Achievements of Breast Cancer Research in the UK
Professor David Cameron, UK

www.breastcancerconference.org

SYMPOSIA & CONFIRMED SPEAKERS:

Highlights of 2017

Basic	Professor Clare Isacke, UK
Translational	Professor Peter Schmid, UK
Early Disease	Dr Michael Gnant, Austria
Late Disease	Dr Mark Verrill, UK

Metastatic Disease

Managing ER+ disease	Professor Stephen Johnston, UK
Predicting outcome in metastatic breast cancer	Dr Aleix Prat, Spain
Evolution of resistance	Dr Adrian Harris, UK

Ductal Carcinoma In Situ

How should we address overdiagnosis and overtreatment of DCIS?	Dr Laura Esserman, USA
How wide a margin do we need for DCIS?	Professor Sarah Pinder, UK
Should radiotherapy be routinely recommended after wide local excision of DCIS?	Professor David Dodwell, UK

Model systems

PDX models	Dr Rob Clarke, UK
Organoid models	Dr Mathew Garnett, UK
3D in vitro modelling using material from Breast Cancer Now Tissue Bank	Dr Richard Grose, UK

Neoadjuvant therapy

Neoadjuvant therapy as a surgical tool	Professor Mike Dixon, UK
Treatment of the axilla post Neoadjuvant chemotherapy	Dr Judy Boughey, USA
RCB vs PCR as an end-point	Dr Fraser Symmans, USA
Latest data on imaging end-points for Neoadjuvant therapy	Dr Sarah Vinnicombe, UK

Image analysis for scientists and pathologists

Image analysis for capturing stromal epithelial interaction	Dr Yinyin Yuan, UK
Using digital pathology in translational breast cancer research	Professor Val Speirs, UK
Imaging-based analysis of ErbB/HER signaling dimer and immunoregulatory molecules – from preclinical science to biomarker discovery	Professor Tony Ng, UK

Measuring and managing breast cancer risk

Stratification to screening	Professor Fiona Gilbert, UK
Risk prediction for risk reduction	Professor Gareth Evans, UK
Findings from the Generations study	Professor Tony Swerdlow, UK
Identifying genetic risk in the prevalent breast cancer population	Professor Nazneen Rahman, UK

Triple Negative Breast Cancer

Biology of new targets	Professor Andrew Tutt, UK
Complexities of TNTs	Dr Chuck Perou, USA
Immunologic advances	Dr Giuseppe Curigliano, Italy

Breast Cancer Heterogeneity and Evolution

Genetic aspects	Dr Lucy Yates, UK
Experimental modelling of heterogeneity	Dr Rachael Natrajan, UK
Relevance to the histopathologist	Dr Fraser Symmans, USA

New treatments and measuring their impact

CDK4/6 inhibition	Dr Nick Turner, UK
New Selective Oestrogen Receptor Downregulators	Dr Lesley-Ann Martin, UK
Liquid biopsies	Professor Jacqui Shaw, UK

Lobular Breast Cancer

Biologic aspects	Dr Steffi Oesterreich, USA
Genetic aspects	Dr Elinor Sawyer, UK
Histologic dilemmas	Professor Ian Ellis, UK
Should lobular phenotype be considered when deciding treatment?	Professor Michael Kerin, Ireland

Biomarkers and prognostic profiling	
Lessons from molecular subtyping	Professor Carlos Caldos, UK
Clinical utility of molecular profiles	Professor Rob Stein, UK
Identifying who needs extended adjuvant ET	Dr Dan Hayes, USA
Mutation-directed therapy	Professor Fabrice André, France

Challenges of local management	
Management and follow up of patients presenting with breast cancer in axillary lymph nodes and occult breast primary	Dr Andreas Makris, UK
When is local surgery indicated in metastatic breast cancer?	Miss Nicola Roche, UK
What is the impact of MRI scanning on breast cancer treatment?	Dr Ulrich Bick, Germany Dr Charlotte Coles, UK
Current and future indications for partial breast radiotherapy	Charlotte Coles, UK

Costs of Treatment	
From price to value: Keeping breast cancer care affordable	Dr Richard Sullivan, UK
Critically examining the true value of our therapies: The only way to meaningful gains in breast cancer	Dr Tito Fojo, USA

Novel Clinical Trial End-points	
Why do we need better trial end-points?	Professor Judith Bliss, UK
Novel trial endpoints: opportunities & challenges for new surrogate endpoints	Dr Marc Buyse, Belgium/USA

A practical guide to shared decision making: Putting research into practice Chaired by Professor Debbie Fenlon & Mrs Lesley Turner	
The benefits of shared decision making	Professor Diana Harcourt, UK
What can help to help make a good decision in a difficult situation like breast cancer?	Dr Alex Clarke, UK
Tools available to support shared decision making	Dr Nicole Paraskeva, UK

Additional Symposia	
Communicating Risk in the Context of Genomic Testing	Professor Sir David Spiegelhalter, UK Dame Lesley Fallowfield, UK
Clinical Trials Roadshow	Chaired by Professor Daniel Rea

Submitted Papers and content	
Free communication/oral presentation of submitted papers	
Poster abstract session	

CPD: The UK IBCS provides 15 CPD credits in accordance with the CPD Scheme of the Royal College of Radiologists

CALL FOR ABSTRACTS

We invite abstracts of proffered papers on experimental biology, etiology, prevention, diagnosis, surgical, medical and radiotherapy treatment of breast cancer and premalignant breast disease.

Abstracts are welcome from all professional disciplines as well as patient representatives.

Those abstracts judged to be of major interest will be selected for oral presentation; the majority will be selected for poster presentation.

All accepted abstracts, other than those that are withdrawn prior to publication, will be published in ***Breast Cancer Research and Treatment***.

Abstracts will be accepted that have been previously presented at SABCS 2017 and published by Cancer Research.

Visit: www.breastcancerconference.org for details of abstract submission

REGISTRATION FEES

Registration is now open. Early bird registration will close on 30th November. Registration will close on 31st December. Visit www.breastcancerconference.org to register

CATEGORY	Early bird – on or before 30/11/17	After 30/11/17
Clinical and academic consultants; Professors	£225	£300
Non-consultant clinicians	£185	£250
Non-clinical research team leaders and post-docs	£185	£250
Nurses; radiographers; research and data managers	£160	£210
Students, including medical undergraduate; PhD and MDRes students	£160	£210
Patients, carers and advocates	£75	£100
Industry	£375	£500

ACCOMMODATION

Marketing Manchester Convention Bureau is the official accommodation provider for UK Interdisciplinary Breast Cancer Symposium 2018.

To book accommodation for this event, please use the following link:

<https://aws.passkey.com/go/BreastCancerSymposium2018>

All rooms are held on an on-line system, allowing you to book and secure your own accommodation using either pro-forma invoices or credit/debit card. If you require any assistance with your reservation, support is available via the Accommodation Booking Team.

The special negotiated delegate rates will be available to book until the end of the day on 18th December 2017, so please book as soon as possible to guarantee a room. If you require accommodation beyond this date or you have any queries about the website, please contact **Marketing Manchester Convention Bureau**.

Contacts

For all accommodation enquiries please call the Accommodation Booking Team on:

0161 238 4563 / 4514

or email: abs@visitmanchester.com

Executive Committee members: Mitch Dowsett (Chair), Judith Bliss, Lucy Davies, Ian Ellis, Julia Gee, Ingunn Holen, Andreas Makris, Ursula van Mann, Anthony Maxwell, Polly McGivern, Arnie Purushotham, Mark Sibbering.

HOSTED BY:

breast cancer
now



British Breast Group